| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
BLA Submission example | BLA | — | Subscribe to access the data. | Enzyme Replacement Therapies (ERT) | Rare Diseases | ||
BLA Submission example | BLA | — | Subscribe to access the data. | Enzyme Replacement Therapies (ERT) | Rare Diseases | ||
BLA Submission example | BLA | — | Subscribe to access the data. | Enzyme Replacement Therapies (ERT) | Rare Diseases |
Recent Updates
Recently added Catalysts
Spruce Biosciences, Inc.$50.07
-1.67 (-3.23%)
D 30Pipeline Score Overvalued Biotech · Clinical
Market Cap
140.57 M
EPS
-37.70
P/E Ratio
-
Value Trade
3.23 M
SEC Financials
Q1 2026Dilution Risk
35%R&D Expenses
7.58 M
Operating CF
-8.73 M
Total Assets
56.17 M
Total Liabilities
21.52 M
Equity
34.65 M
D/E Ratio
12,345
-11.82 %
Week
-10 %
1 Month
-3.27 %
3 Month
-49.48 %
6 Month
-95.61 %
5 Year
-96.25 %
All Time
Cash Data
Cash Position
54.08 M
Monthly Burn
2.91 M
Runway
16.9 mo
Burn Trend
StableSEC Filing
May 13, 2026
Overview
Volume
56.52 K
52 Week Range
4.35 - 240
% held by Insiders
16.68 %
% held by Institutions
25.6 %
Enterprise Value
93.61 M
Total Shares
2.75 M
Short %
14.47 %
Float Shares
2.48 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Spruce Biosciences, Inc.
170Total events
9Upcoming
39Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 9
TBD
T2PRV Granted
PRV program reauthorization through September 2029 noted; TA-ERT eligible for PRV if approved
Event history 161
Jul 8, 2026
◆Oral PresentationPresentation
Spruce Biosciences to present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
Jun 15, 2026
◆Management ChangeCorporate
Appointment of Eric Jordan as VP, Marketing and Tina Gullotta as VP, Finance and Corporate Controller
Jun 8, 2026
◆Oral PresentationPresentation
Long-term tralesinidase alfa ERT data presented at 18th International MPS Symposium
Sanfilippo Syndrome Type B (MPS IIIB)source ↗
Jun 6, 2026
◆Oral Presentationtralesinidase alfaPresentation
Long-term data on tralesinidase alfa enzyme replacement therapy (TA-ERT) presented at 18th International MPS Symposium
Sanfilippo Syndrome Type B (MPS IIIB)source ↗
May 4, 2026
Apr 21, 2026
Apr 20, 2026
Drug Pipeline Intelligence
D30
Pipeline Score $41M
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.3x
rNPV / MCap Top 34%
Micro Cap (rank 602 of 911)
Percentile RankSpruce Biosciences, Inc. faces pipeline headwinds (30/100), with $275M risk-adjusted pipeline value, led by Tralesinidase alfa in MPS IIIB (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tralesinidase alfa Small molecule | MPS IIIB | Phase 3 | NCT07579910 | 50% | $218M | NOT YET_RECRUITING | 14 | - | D (39) | Aug 1, 2033 | - | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
tralesinidase alfa Breakthrough | Sanfilippo Syndrome Type B (MPS IIIB) | — | 2026-02-06 | TA-ERT treatment stabilized and preserved cognitive and non-cognitive outcomes for over six-year period; 22 patients followed up to six years; sustained normalization of CSF HS-NRE Read More | Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB) Read More | |
tralesinidase alfa Breakthrough | Sanfilippo Syndrome Type B (MPS IIIB) | — | 2026-02-06 | TA-ERT treatment stabilized and preserved cognitive and non-cognitive outcomes for over six-year period; 22 patients followed up to six years; sustained normalization of CSF HS-NRE Read More | Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB) Read More | |
tralesinidase alfa Breakthrough | Sanfilippo Syndrome Type B (MPS IIIB) | — | 2026-02-06 | TA-ERT treatment stabilized and preserved cognitive and non-cognitive outcomes for over six-year period; 22 patients followed up to six years; sustained normalization of CSF HS-NRE Read More | Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB) Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SPRB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SPRB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SPRB▼ -3.2%today
Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
Spruce Biosciences, a late-stage biopharmaceutical company, announced its participation in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit. CEO Javier Szwarcberg will engage in a fireside chat, showcasing the company's commitment to addressing neurological disorders. This event underscores the company's ongoing efforts in the healthcare sector.
Read more →SPRBSpruce Biosciences Joins the Russell 3000® Index
Spruce Biosciences has been added to the Russell 3000® Index, which includes the largest U.S. companies. This inclusion may enhance the company's visibility and attract more investors. The Russell 3000® Index is a benchmark for U.S. equity performance, representing a broad spectrum of the market.
Read more →SPRBSpruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs
Spruce Biosciences has appointed Agnieszka Jurecka, M.D., Ph.D., MPH, as the new Vice President of Medical Affairs. This strategic move is aimed at enhancing the company's leadership in medical affairs. Dr. Jurecka brings extensive experience and expertise to the role, which is expected to support Spruce's ongoing initiatives.
Read more →SPRBSpruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller
Spruce Biosciences has appointed Eric Jordan as Vice President of Marketing and Tina Gullotta as Vice President of Finance and Corporate Controller. This leadership change aims to strengthen the company's marketing and financial strategies. The appointments reflect the company's commitment to enhancing its operational capabilities.
Read more →SPRBSpruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium
Spruce Biosciences announced the presentation of long-term data on Tralesinidase Alfa, an enzyme replacement therapy for Sanfilippo Syndrome Type B (MPS IIIB), at the 18th International MPS Symposium. The announcement highlights the company's ongoing commitment to addressing this rare genetic disorder. Details regarding the specific findings or implications of the data were not provided in the article.
Read more →SPRBSpruce Biosciences Announces Data Presentation at the 18th International MPS Symposium
Spruce Biosciences has announced a data presentation at the 18th International MPS Symposium. The event is significant for showcasing advancements in the field. However, specific details about the data or findings were not disclosed in the announcement. The presentation is expected to attract attention from industry professionals.
Read more →SPRBSpruce Biosciences to Participate in Upcoming Conferences in June
Spruce Biosciences is scheduled to participate in several conferences in June. The details regarding the specific conferences and topics of discussion have not been disclosed. This participation may provide opportunities for networking and showcasing their developments in the biopharma sector.
Read more →SPRBSpruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Spruce Biosciences has released its financial results for the first quarter of 2026 along with corporate updates. The report provides insights into the company's performance and strategic direction. Further details on specific financial metrics or corporate developments were not disclosed in the article.
Read more →SPRBSpruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations
Spruce Biosciences has announced the appointment of Brian Walls as Vice President of Market Access and Darren Johnson as Vice President of Commercial Operations. These appointments are aimed at strengthening the company's commercial leadership team. The announcement reflects the company's commitment to enhancing its market presence and operational efficiency.
Read more →SPRB▼ -26%on this news
Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Spruce Biosciences has priced its public offering at $50 per share, aiming to raise $60 million. The offering includes 1,150,000 shares of common stock and 50,000 pre-funded warrants. The expected closing date is April 22, 2026, pending customary conditions. The company is focused on developing therapies for neurological disorders.
Read more →SPRBSpruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Spruce Biosciences has announced a proposed public offering of common stock and pre-funded warrants. The details regarding the number of shares and pricing have not been disclosed. This move is part of the company's strategy to raise capital, although specific uses for the funds have not been outlined.
Read more →SPRB▲ +11.2%on this news
Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer
Spruce Biosciences has appointed Dale Hooks as Chief Commercial Officer, bringing nearly 35 years of experience in pharmaceutical marketing. Hooks has a proven track record with 21 product launches and leadership roles in rare diseases. His expertise will be crucial as the company prepares for the biologics license application for TA-ERT, aimed at treating Sanfilippo Syndrome Type B.
Read more →SPRB▲ +11.2%on this news
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates
Spruce Biosciences reported its financial results for 2025 and provided updates on its TA-ERT program for Sanfilippo Syndrome Type B. The company is on track to submit a Biologics License Application (BLA) in Q4 2026, following positive discussions with the FDA. Additionally, Dale Hooks has been appointed as Chief Commercial Officer to bolster commercial efforts, and the company secured $50 million in growth capital.
Read more →SPRBSpruce Biosciences to Present at Upcoming Investor Conferences in March 2026
Spruce Biosciences, a late-stage biopharmaceutical company, announced that CEO Javier Szwarcberg will present at two investor conferences in March 2026. The presentations aim to highlight the company's focus on developing therapies for neurological disorders. Interested parties can access live webcasts and archived copies on the company's website.
Read more →SPRB▼ -8.2%on this news
Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
Spruce Biosciences announced positive outcomes from Type B meetings with the FDA regarding its upcoming biologics license application (BLA) for TA-ERT, aimed at treating Sanfilippo Syndrome Type B. The FDA acknowledged the potential for using CSF HS-NRE as a surrogate endpoint for accelerated approval. The BLA submission is now anticipated in Q4 2026 to meet specific regulatory requirements.
Read more →SPRB▼ -8.2%on this news
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Spruce Biosciences, a late-stage biopharmaceutical company, announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference. CEO Javier Szwarcberg will engage in a fireside chat on February 25, 2026. This event underscores the company's commitment to developing therapies for neurological disorders with significant unmet needs.
Read more →SPRBLong-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)
Spruce Biosciences presented long-term data at the WORLDSymposium showing that tralesinidase alfa enzyme replacement therapy (TA-ERT) effectively reduces heparan sulfate levels and stabilizes cognitive and motor functions in patients with Sanfilippo Syndrome Type B. The therapy's safety profile remains consistent over six years, supporting its potential as a first disease-modifying treatment for this condition.
Read more →SPRB▼ -10.6%on this newsshared move
Long -Term Data Presented at the 22 nd Annual WORLD Symposium Highlights Tralesinidase Alfa Enzyme Replacement Therapy's Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)
Spruce Biosciences presented long-term data at the 22nd Annual WORLD Symposium, highlighting the effectiveness of tralesinidase alfa enzyme replacement therapy (TA-ERT) for patients with Sanfilippo Syndrome Type B. The treatment demonstrated significant stabilization in cognitive and motor skills over a six-year period compared to natural history patients. Notably, the TA-ERT treatment also normalized levels of heparan sulfate in cerebrospinal fluid, indicating substantial clinical benefits. This data is crucial as it supports the therapy's potential as the first disease-modifying option for this devastating condition.
Read more →SPRB▼ -5.1%on this news· ran to -15% by day 1shared move
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team
Spruce Biosciences has appointed Daven Mody as Senior Vice President of Regulatory and Quality and Bruno Gagnon as Senior Vice President of Clinical Development Operations. These appointments come as the company prepares for a BLA submission for its enzyme replacement therapy for Sanfilippo Syndrome Type B. Both leaders bring extensive experience in their respective fields, which is expected to bolster Spruce's strategic initiatives.
Read more →SPRBSpruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™
Spruce Biosciences announced that it will present data on its enzyme replacement therapy, tralesinidase alfa, at the upcoming WORLDSymposium 2026. The presentations will include findings on the therapy's long-term effects on patients with Sanfilippo syndrome type B, showcasing improvements in cognitive function and brain volume. Additionally, divergent outcomes in two siblings receiving different treatments will be discussed.
Read more →SPRBHarbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
Harbour BioMed has acquired common stock in Spruce Biosciences, increasing its stake to approximately 3.8%. This acquisition marks a significant milestone in their collaboration, transitioning from a traditional licensor-licensee relationship to a strategic partnership. The collaboration focuses on advancing SPR202, a monoclonal antibody aimed at treating disorders like congenital adrenal hyperplasia.
Read more →SPRB▼ -5.6%on this news
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital Initial Funding of $15 Million from the First of Four Tranches, Extending Cash Runway into 2027 Facility Will Support Advancement and Pot
Spruce Biosciences has secured a growth capital loan facility totaling up to $50 million with Avenue Capital, which includes an initial $15 million tranche. This funding aims to extend the company's operational runway into 2027 while supporting the development of TA-ERT, a potential disease-modifying therapy for MPS IIIB. The agreement highlights Spruce's efforts to address significant unmet medical needs in treating this condition, but future funding tranches are dependent on meeting key milestones.
Read more →SPRB▼ -9%on this news
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates Granted Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the Treatment of Sanf
Spruce Biosciences reported its financial results for Q3 2025 and provided updates on its development efforts. The company received FDA Breakthrough Therapy Designation for its enzyme replacement therapy, TA-ERT, aimed at treating MPS IIIB. Furthermore, Spruce completed a $50 million private equity financing, which is expected to support the development and regulatory submission of TA-ERT, planned for early 2026. Overall, the company is positioning itself for significant advancements in the treatment of children impacted by this condition.
Read more →SPRB▼ -11.1%on this news
Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrates Profound and Durab
Spruce Biosciences has reported its financial results for the second quarter of 2025 and provided updates on its pipeline. The integrated long-term clinical data for TA-ERT indicate significant efficacy and safety in treating patients with Sanfilippo Syndrome Type B, with a submission for its Biologics License Application expected in early 2026. Additionally, the company has initiated a Phase 2 trial for tildacerfont, a treatment for Major Depressive Disorder, which aims to address a specific patient subgroup. The company also announced steps towards relisting on the Nasdaq following a reverse stock split.
Read more →SPRBSpruce Biosciences Announces Reverse Stock Split Spruce's Common Stock to Begin Trading on a Post-Split Adjusted Basis on
Spruce Biosciences has announced a 1-for-75 reverse stock split effective August 4, 2025, aiming to comply with Nasdaq's minimum bid price rules. The split was approved by stockholders and aims to reduce outstanding shares from approximately 42.2 million to around 0.6 million. Post-split trading is expected to commence on August 5, 2025. Shareholders will receive cash for any fractional shares rather than issuing them, maintaining their relative equity interests. The company must sustain compliance with Nasdaq regulations to avoid delisting.
Read more →SPRBSpruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates Acquisition of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the Treatment of Sanfilippo Syndrome Type B (MPS II
Spruce Biosciences, Inc. has reported its financial results for Q1 2025 and announced key corporate updates regarding the acquisition of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for Sanfilippo Syndrome Type B. The company plans to submit a Biologics License Application (BLA) to the U.S. FDA in the first half of 2026, reflecting a significant step towards addressing an unmet need in treating MPS IIIB. Financially, Spruce reported an increased net loss compared to the previous year, although it also highlighted progress in regulatory designations for its therapy. Future studies and operational plans aim to secure accelerated approval and enhance patient access to their therapies.
Read more →SPRB▼ -58%on this news
Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) Biologics License Application (BLA) Submission to U.S. FDA for Tralesin
Spruce Biosciences has announced a new corporate strategy that includes the acquisition of Tralesinidase Alfa (TA-ERT), aimed at treating Sanfilippo Syndrome Type B. The company plans to submit a Biologics License Application (BLA) to the U.S. FDA in the first half of 2026, having received positive feedback regarding the use of a biomarker for accelerated approval. With no current FDA-approved treatments for this condition, TA-ERT represents a potential significant advancement for affected patients and their families. Spruce aims to build a specialized commercial organization to support this therapeutic's launch, highlighting its commitment to rare diseases with unmet medical needs.
Read more →SPRBSpruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates Topline Data from CAHmelia-204 Study of Tildacerfont in Adult Congenital Adrenal Hyperplasia (CAH) Anticipated in December 20
Spruce Biosciences has reported its financial results for Q3 2024, alongside updates on clinical trials for tildacerfont in treating congenital adrenal hyperplasia (CAH). The company anticipates topline results from two pivotal studies involving both adult and pediatric populations in December 2024. Financially, Spruce has a cash runway that extends through the end of 2025, although it recorded a net loss of $8.7 million in the third quarter. Collaboration revenue has also decreased year-over-year, raising questions about future revenue generation.
Read more →SPRBSpruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates Announced Strategic Collaboration with HMNC Brain Health GmbH (HMNC) to Develop Tildacerfont for the Treatment of Major Depr
Spruce Biosciences announced its financial results for Q2 2024, revealing a strategic collaboration with HMNC Brain Health to explore tildacerfont's potential in treating Major Depressive Disorder. Key upcoming milestones include topline data from two clinical trials in Q4 2024, with strong cash reserves projected to support operations through 2025. However, the company reported an increased net loss and high R&D expenses compared to the previous year.
Read more →SPRBSpruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates Analyses of Data from CAHmelia-203 in Adult Congenital Adrenal Hyperplasia (CAH) Demonstrate Correlation Between Tildacerfont
Spruce Biosciences announced its financial results for Q1 2024, highlighting positive data from the CAHmelia-203 trial. The study indicated a significant mean reduction in ACTH levels, suggesting effective engagement with the target mechanism of the drug tildacerfont. The company anticipates reporting additional data from the CAHmelia-204 trial in the third quarter of 2024, with expectations for favorable outcomes. Despite ongoing financial losses, Spruce's cash reserves are projected to sustain operations until the end of 2025.
Read more →SPRBSpruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates CAHmelia-203 Study of Tildacerfont in Adult Classic Congenital Adrenal Hyperplasia (CAH) with Severe Hyperandrogenemia Did Not Me
Spruce Biosciences has released its full year 2023 financial results and provided updates on clinical studies. The CAHmelia-203 study of Tildacerfont in adults with classic congenital adrenal hyperplasia failed to meet its primary efficacy endpoint. However, positive data from the CAHptain-205 study in pediatric patients shows promise for further development. The company has prioritized resources and implemented cost reductions to extend its cash runway through the end of 2025, while looking forward to upcoming topline results from the CAHmelia-204 study in 2024.
Read more →SPRBSpruce Biosciences Provides Clinical Program Updates and Outlook for 2024 Catalyst-Heavy 2024 with Topline Results from CAHmelia-203 in Adult Classic Congenital Adrenal Hyperplasia (CAH) and CAHptain-205 in Pediatric Cla
Spruce Biosciences has provided updates on its clinical programs, highlighting the completion of enrollment in multiple trials for tildacerfont, aimed at treating classic congenital adrenal hyperplasia (CAH). Results from the CAHmelia-203 and CAHptain-205 trials are expected in March 2024, while topline results from CAHmelia-204 will follow in Q3 2024. The company maintains a strong cash position, allowing operations to continue well into 2025, however, it also acknowledges risks associated with its forward-looking statements regarding trial outcomes.
Read more →SPRBSpruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates Enrollment Completed in CAHptain-205 Study in Pediatric Classic Congenital Adrenal Hyperplasia (CAH) Target Enrollment Comple
Spruce Biosciences has announced the completion of target enrollment in its CAH studies, including CAHptain-205 for pediatric patients and CAHmelia-203 for adults with classic congenital adrenal hyperplasia (CAH). Despite the positive milestone, the company reported a net loss of $12.4 million for Q3 2023, compounded by rising research and development expenses. Looking ahead, Spruce plans to release topline data from these studies in early 2024, potentially enhancing the therapeutic landscape for individuals with CAH.
Read more →SPRBSpruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates Spruce Reports Interim Data from Phase 2 POWER Proof-of-Concept Study in Polycystic Ovary Syndrome (PCOS) CAHmelia Program i
Spruce Biosciences reported its second quarter financial results, highlighting interim data from the Phase 2 POWER study for PCOS, which suggests that tildacerfont may effectively reduce DHEAS levels. The company is approaching 75% enrollment in both the CAHmelia-203 and CAHmelia-204 trials for classic CAH, indicating strong interest in the studies. Additionally, the appointment of Heidi Petersen as Senior VP of Regulatory and Quality is expected to enhance the company's operational capabilities as it advances towards potential therapy submissions. However, the company continues to report significant net losses and rising R&D expenses.
Read more →SPRBSpruce Biosciences Reports First Quarter 2023 Financial Results and Provides Corporate Updates CAHmelia Program in Adult Classic Congenital Adrenal Hyperplasia (CAH) Achieves 50% Enrollment in CAHmelia-204 and Approaches
Spruce Biosciences reported its first quarter 2023 financial results, highlighting significant progress in its clinical trials for congenital adrenal hyperplasia (CAH). The company achieved 50% enrollment in the CAHmelia-204 trial and completed enrollment in the P.O.W.E.R. study for polycystic ovary syndrome (PCOS). Additionally, Cohort 1 of the CAHptain study in pediatric classic CAH has been fully enrolled. The company also announced a strategic partnership with Kaken Pharmaceutical for the commercialization of its product candidate in Japan.
Read more →SPRBSpruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate Updates CAHmelia-203 in Adult Classic CAH Surpasses 50% Enrollment Private Placement Financing of $53.6 million in Gross Proceeds with To
Spruce Biosciences has announced its full-year financial results for 2022, highlighting significant advancements in clinical trials and financing efforts. The company surpassed 50% enrollment in its CAHmelia-203 study for adult classic congenital adrenal hyperplasia, with topline data expected in late 2023. A private placement financing raised $53.6 million, complemented by a strategic partnership with Kaken Pharmaceutical to develop tildacerfont in Japan. Despite these positives, Spruce reported an increased net loss and rising R&D expenses for the year.
Read more →SPRB▲ +6.1%on this news
Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates CAHmelia-203 Approaching 50% Enrollment; CAHmelia-204 Recently Surpassed 25% Enrollment Appointment of Saba Sile, M.D., as Vi
Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates CAHmelia-203 Approaching 50% Enrollment; CAHmelia-204 Recently Surpassed 25% Enrollment Appointment of Saba Sile, M.D., as Vice President of Clinical Development San Francisco, Calif
Read more →SPRBSpruce Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update Abstract Accepted for Oral Presentation at International Congress of Endocrinology (ICE 2022) Appointment of P.J. Ramtin as S
Spruce Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update Abstract Accepted for Oral Presentation at International Congress of Endocrinology (ICE 2022) Appointment of P.J. Ramtin as Senior Vice President of Business Operations Expansion of
Read more →SPRB▼ -10.5%on this news
Spruce Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update 25% Enrollment Achieved in CAHmelia-203 Study for Adult Classic CAH; On Track to Report Topline Data in 2H 2023 Debt Facility
Spruce Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update 25% Enrollment Achieved in CAHmelia-203 Study for Adult Classic CAH; On Track to Report Topline Data in 2H 2023 Debt Facility with Silicon Valley Bank Amended to Provide Up to $10 Mill
Read more →SPRBSpruce Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates Topline Safety Data from Cohort 1 of Pediatric Classic CAH Study Expected by 1H 2023 Will Charlton, M.D., M.A.
Spruce Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates Topline Safety Data from Cohort 1 of Pediatric Classic CAH Study Expected by 1H 2023 Will Charlton, M.D., M.A.S., Appointed Chief Medical Officer San Francisco, Calif.
Read more →SPRB▼ -15.6%on this news
Spruce Biosciences Appoints Javier Szwarcberg, M.D., MPH as Chief Executive Officer - Samir Gharib, MBA, Promoted to President - San Francisco, Calif.
Spruce Biosciences Appoints Javier Szwarcberg, M.D., MPH as Chief Executive Officer - Samir Gharib, MBA, Promoted to President - San Francisco, Calif. - Jan. 5, 2022 - Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and comm
Read more →SPRBSpruce Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Updates Planned Initiation of Phase 2 Programs in Pediatric Classic CAH and Polycystic Ovary Syndrome Late-Stage CAHmelia Program in
Spruce Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Updates Planned Initiation of Phase 2 Programs in Pediatric Classic CAH and Polycystic Ovary Syndrome Late-Stage CAHmelia Program in Adult Classic CAH Expanded to Sites in Australia and Canad
Read more →SPRBFORWARD-LOOKING STATEMENTS 2 This presentation contains forward-looking statements about Spruce Biosciences, Inc. ("we," "Spruce" or the "Company"). All statements other than statements of historical facts contained in t
Baird 2021 Global Healthcare Conference Focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need Spruce BIOSCIENCES Exhibit 99.1 FORWARD-LOOKING STATEMENTS 2 This presentation contains forward-looking statements a
Read more →SPRBFORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements about Spruce Biosciences, Inc. ("we," "Spruce" or the "Company"). All statements other than statements of historical facts contained in thi
Research and Development Day Tildacerfont for Adult and Pediatric Classic CAH August 25, 2021 Exhibit 99.1 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements about Spruce Biosciences, Inc. ("we," "Spruce" or the "Company"). All statements other than
Read more →SPRBSpruce Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Updates Clearance of IND for Treatment of Polycystic Ovary Syndrome New Patent Broadens Tildacerfont Intellectual Property Estate in
Spruce Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Updates Clearance of IND for Treatment of Polycystic Ovary Syndrome New Patent Broadens Tildacerfont Intellectual Property Estate in Congenital Adrenal Hyperplasia Publication of Tildacerfo
Read more →SPRBSpruce Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Updates Presentation of Phase 2 Data of Tildacerfont at 23 rd Annual European Congress of Endocrinology Cash and Cash Equivalents of
Spruce Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Updates Presentation of Phase 2 Data of Tildacerfont at 23rd Annual European Congress of Endocrinology Cash and Cash Equivalents of $148.6 million San Francisco, Calif. - May 12, 2021 - Spru
Read more →SPRBSpruce Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Recent Corporate Updates Late-Stage CAHmelia Program in Adult Classic CAH Advancing with Majority of Study Sites Active CAHmelia
Spruce Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Recent Corporate Updates Late-Stage CAHmelia Program in Adult Classic CAH Advancing with Majority of Study Sites Active CAHmelia Program Enhanced Following Discussions with FDA - Primary
Read more →SPRBSpruce Biosciences Provides Corporate Update and Outlines Milestones for 2021 - CAHmelia Adult Classic CAH Program Underway in U.S. and Europe- -Initiation of Phase 2 Pediatric Classic CAH Program Anticipated in Second H
Spruce Biosciences Provides Corporate Update and Outlines Milestones for 2021 - CAHmelia Adult Classic CAH Program Underway in U.S. and Europe- -Initiation of Phase 2 Pediatric Classic CAH Program Anticipated in Second Half of 2021- -Initiation of Phase 2 Polycystic Ovary Synd
Read more →SPRBSpruce Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update -Successful Initiation of Late-Stage CAHmelia Program in Adult Classic CAH- -FDA and EMA Scientific Advice Support Plans in Pe
Spruce Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update -Successful Initiation of Late-Stage CAHmelia Program in Adult Classic CAH- -FDA and EMA Scientific Advice Support Plans in Pediatric Classic CAH Program- -IPO Results in Pro Forma Ca
Read more →SPRBSpruce Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares San Francisco, Calif.
Spruce Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares San Francisco, Calif. October 14, 2020 Spruce Biosciences, Inc., a late-stage biopharmaceutical company focused on developing and comm
Read more →Competitive Position
How SPRB ranks across every disease it competes inCompetitive Position is a premium feature
See how SPRB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial